BRAF and melanoma: The favorable impact of neutrophils on melanoma cells was not confined to targeted therapy; it was also evident in cisplatin-treated conditions, thereby expanding the neutrophil-induced protection to other treatment regimens, which can be applied independent of the prevalence of BRAF mutations.